Authors: Adam Z. 1; Řehák Z. 2; Krejčí M. 1; Boichuk I. 1; Pour L. 1 Authors‘ workplace: Interní hematologická a onkologická klinika LF MU a FN Brno 1; Oddělení nukleární medicíny, MOÚ Brno 2 Published in: Klin Onkol 2026; 39(1): 31-39 Category: Review doi: https://doi.org/10.48095/ccko202631
Background: Monoclonal immunoglobulin and/or free light chains cause diverse complications that can affect almost all tissues or organs. Aim: Monoclonal immunoglobulin can interfere with hemostasis and cause both hypercoagulation or hemorrhagic diathesis. In patients with non-malignant gammopathy and untreated multiple myeloma, thrombotic complications are more common than hemorrhagic complications. Exceptionally, monoclonal immunoglobulin can also exhibit the properties of an autoantibody and cause diverse organ damage. Among the more common forms, there is cold agglutinin disease, neuropathy, and various forms of eye damage. In the text, less common disorders are also mentioned. Conclusion: All the complications described in the text may be caused by monoclonal immunoglobulin, but they can also have other causes. If it is possible to establish an etiopathogenetic connection of these problems with monoclonal immunoglobulin, then targeted treatment that suppresses its production may lead to the disappearance of the problem.
free light chains – monoclonal immunoglobulin – monoclonal gammopathy of clinical significance – MGCS
1. Gkalea V, Fotiou D, Dimopoulos MA et al. Monoclonal gammopathy of thrombotic significance. Cancers (Basel) 2023; 15 (2): 480. doi: 10.3390/cancers15020480.
2. Gkalea V, Fotiou D, Kastritis E. More on monoclonal gammopathy of thrombotic significance. N Engl J Med 2024; 391 (15): 1463–1464. doi: 10.1056/NEJMc2411324.
3. Rögnvaldsson S, Gasparini A, Thorsteinsdottir S et al. Monoclonal gammopathy of undetermined significance and the risk of thrombotic events: results from iStopMM, a prospective population-based screening study. Br J Haematol 2025; 206 (3): 899–906. doi: 10.1111/bjh.19957.
4. Radocha J, Maisnar V. Tromboprofylaxe u monoklonálních gamapatií. Cesk Geriatr Revue 2007; 5 (3): 129–133.
5. Dulíček P, Maisnar V. Možné klinické projevy přítomnosti M-Ig. Změny hemostázy vlivem přítomnosti monoklonálního imunoglobulinu. Monoklonální imunoglobuliny – výskyt, význam a možnosti jejich průkazu. Praha: Nucleus HK 2012 : 90–92.
6. Špička I, Cieslar P, Hrkal Z et al. Vliv paraproteinu na antitrombotické mechanismy – další typ interference paraproteinu s hemostázou. Cas Lek Cesk 1996; 135 (4): 126–127.
7. Chen H, Zhang Y, Wang Z et al. Thrombotic events in patiens with multiple myeloma and their impact on overall survival. Hematology 2025; 30 (1): 2464316. doi: 10.1080/16078454.2025.2464316.
8. Kanack AJ, Schaefer JK, Sridharan M et al. Monoclonal gammopathy of thrombotic/thrombocytopenic significance. Blood 2023; 141 (14): 1772–1776. doi: 10.1182/blood.2022018797.
9. Kanack AJ, Leung N, Padmanabhan A. Diagnostic complexity in monoclonal gammopathy of thrombotic significance. N Engl J Med 2024; 391 (20): 1961–1963. doi: 10.1056/NEJMc2409428.
10. Mainville L, Coitoru D. Monoclonal gammopathy of thrombotic significance. Br J Dermatol 2025; 193 (4): 807. doi: 10.1093/bjd/ljaf144.
11. Siddiq N, Bergstrom C, Anderson LD et al. Bleeding due to acquired dysfibrinogenemia as the initial presentation of multiple myeloma. BMJ Case Rep 2019; 12 (7): e229312. doi: 10.1136/bcr-2019-229312.
12. Zhang S, Chen Z, Huang M et al. Monoclonal gammopathy of undetermined significance (MGUS) characterized by refractory lower gastrointestinal postoperative bleeding with coagulopathy. Intractable Rare Dis Res 2022; 11 (4): 206–210. doi: 10.5582/irdr.2022.01120.
13. Ohara F, Suzuki A, Suzuki N et al. Newly diagnosed multiple myeloma with bleeding and coagulation abnormalities caused by a thrombin-inhibiting substance. Int J Hematol 2024; 120 (6): 743–749. doi: 10.1007/s12185-024-03849-2.
14. Trabelsi B, Baccouche H, Eddhib J et al. Acquired factor XIII deficiency and its unprecedented association with multiple myeloma: case report and literature review. Blood Coagul Fibrinolysis 2024; 35 (5): 293–295. doi: 10.1097/MBC.0000000000001311.
15. Vengenechten I, Smejkal P, Zapletal O et al. Analysis of von Willebrand disease in the South Moravian population (Czech Republic): results from the BRNO-VWD study. Thromb Haemost 2019; 119 (4): 594–605. doi: 10.1055/s-0039-1678528.
16. Penka M, Smejkal P, Matýšková M et al. K diagnostice von Willebrandovy choroby. Laboratorní hematologie. Hradec Králové: HK Credit 2006 : 46–48.
17. Drenko P, Přenosilová P, Lavičková A et al. Acquired von Willebrand syndrome (AvWS).Vnitr Lek 2022; 68 (4): E16–E19.
18. Nicol C, Pan-Petesch B, Ianotto JC. Acquired von Willebrand syndrome and lymphoid neoplasms: a review of malignancy management, and propositions of practical recommendations. Haemophilia 2022; 28 (6): 938–949. doi: 10.1111/hae.14648.
19. Galletta E, Galvanin F, Bertomoro A et al. Acquired von Willebrand syndrome in patiens with monoclonal gammopathy of undetermined significance investigated using a mechanistic approach. Blood Transfus 2023; 21 (1): 74–82. doi: 10.2450/2021.0121-21.
20. Abou-Ismail MY, Rodgers GM, Bray PF et al. Acquired von Willebrand syndrome in monoclonal gammopathy – a scoping review on hemostatic management. Res Pract Thromb Haemost 2021; 5 (2): 356–365. doi: 10.1002/rth2.12481.
21. Ghariani I, Braham N, Veyradier A et al. Acquired von Willebrand syndrome: five cases report and literature review. Thromb Res 2022; 218 : 145–150. doi: 10.1016/j.thromres.2022.08.025.
22. Langer AL, Connell NT. Acquired von Willebrand syndrome. Hematol Oncol Clin North Am 2021; 35 (6): 1103–1116. doi: 10.1016/j.hoc.2021.07.005.
23. Mathew Thomas V, Gilreath JA, Newton S et al. Daratumumab as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy. Haemophilia 2021; 27 (4): e563–e566. doi: 10.1111/hae.14323.
24. Shah CP, Delaune J, Mandernach MW. Acquired von Willebrand syndrome in association with multiple myeloma: remission after stem cell transplant. BMJ Case Rep 2021; 14 (1): e239053. doi: 10.1136/bcr-2020 - 239053.
25. Čermák J, Písačka M. Autoimmune hemolytic anemia. Vnitr Lek 2018; 64 (5): 514–519.
26. Gumulec J, Brát R, Kolek M et al. Pre-operative care for cardiac surgery patients with cold antibody disorder, cryoglobulinaemia and cryofibrinogenemia. Vnitr Lek 2009; 55 (3): 236–241.
27. Adam Z, Pejchvalová A, Chlupová G et al. Cold agglutinin disease – no response to glucocorticoids and rituximab, what treatment is best for the 3rd line of therapy? Case report and review of the literature. Vnitr Lek 2013; 59 (9): 828–840.
28. Bozzi S, Umarje S, Hawaldar K et al. Prevalence and incidence of primary autoimmune hemolytic anemia and cold agglutinin disease in the United States, 2016–2023. PLoS One 2025; 20 (6): e0323843. doi: 10.1371/journal.pone.0323843.
29. Jäger U, Barcellini W, Broome CM et al. Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the First International Consensus Meeting. Blood Rev 2020; 41 : 100648. doi: 10.1016/j.blre.2019.100648.
30. Berentsen S, Barcellini W, D‘Sa S et al. Cold aglutinin disease revisited: a multinational observational study od 232 patiens. Blood 2020; 136 (4): 480–488. doi: 10.1182/blood.2020005674.
31. Berentsen S. Cold-antibody autoimmune hemolytic anemia: its association with neoplastic disease and impact on therapy. Curr Oncol Rep 2024; 26 (9): 1085–1096. doi: 10.1007/s11912-024-01569-8.
32. Berentsen S. Treatment of autoimmune hemolytic anemia: novel and investigational approaches. Minerva Med 2025; 116 (3): 249–264. doi: 10.23736/S0026 - 4806.25.09617-X.
33. Piatek C, Murakhovskaya I, Karaouni A et al. Real - -world use of rituximab in the treatment of cold agglutinin disease in the United States: a retrospective study. EJHaem 2025; 6 (4): e70082. doi: 10.1002/jha2.70082.
34. Shima T, Iwasaki H, Henzan T et al. Successful management of total plasma exchange for hemolytic cold agglutinin disease. Intern Med 2025; 64 (1): 119–122. doi: 10.2169/internalmedicine.3606-24.
35. Quartuccio L, Manfrè V, Treppo E et al. Monoclonal Gammopathy of Rheumatologic Significance (MGRhS): a systemic vision of clonal disorders with multiple organ involvement. Autoimmun Rev 2025; 24 (11): 103895. doi: 10.1016/j.autrev.2025.103895.
36. Liang S, Xu W, Zhong P et al. Case report: IgG4-RD-related ophthalmopathy combined with monoclonal gammopathy of undetermined significance. Front Immunol 2025; 16 : 1565388. doi: 10.3389/fimmu.2025.1565388.
37. Cheng Z, Song Y, Zhao S et al. Anti-GluK2 antibody-positive autoimmune encephalitis concurrent with multiple myeloma: a case report. BMC Neurol 2025; 25 (1): 27. doi: 10.1186/s12883-025-04037-3.
38. Musilová L, Kryštůfková O. Monoklonální gamapatie u systémových onemocnění pojiva. Rheumatologia (Bratislava) 2002; 16 (1): 31–36.
39. Jonsson V, Kierkegaard A, Salling S et al. Autoimunity in Waldenström‘s macroglobulinemia. Leukemia Lymphoma 1999; 34 (3–4): 373–379. doi: 10.3109/10428199909050962.
40. Sigurbergsdóttir AÝ, Love TJ, Kristinsson SY. Autoimmunity, infections, and the risk of monoclonal gammopathy of undetermined significance. Front Immunol 2022; 13 : 876271. doi: 10.3389/fimmu.2022.876271.
41. Askeland FB, Frøen HM, Bolstad N et al. Monoclonal insulin autoimmune syndrome successfully treated with plasma cell directed therapy. Clin Lymphoma Myeloma Leuk 2025; 25 (3): e127–e130. doi: 10.1016/j.clml.2024.10.005.
42. Clifford L, Joseph F, Joshi T. A clinical case of insulin autoimmune syndrome with monoclonal gammopathy of uncertain significance; complexity in management. Oxf Med Case Reports 2024; 2024 (6): omae054. doi: 10.1093/omcr/omae054.
43. Adam Z, Kissová J, Pour L et al. Myopathy in patients with Waldenströms macroglobulinemia. A case study and an overview of autoimmune expressions of type IgM monoclonal immunoglobulins. Vnitr Lek 2015; 61 (9): 821–828.
44. Forgáč M, Uher T, Zámečník J. Nemalinová myopatie asociovaná s monoklonální gamapatií – kazuistika. Cesk Slov Neurol N 2014; 77/110 (2): 247–250.
45. Pika T, Folprechtová P, Roubalová L et al. Úspěšná léčba anti MAG neuropatie asociované s monoklonální gamapatií nejistého významu kombinací rituximabu s dexametazonem – kazuistika. Cesk Slov Neurol N 2015; 78/111 (4): 474–476. doi: 10.14735/amcsnn2015474.
46. Le Cann M, Bouhour F, Viala K et al. CANOMAD: a neurological monoclonal gammopathy of clinical significance that benefits from B-cell-targeted therapies. Blood 2020; 136 (21): 2428–2436. doi: 10.1182/blood.2020007092.
47. Traub R, Qarni T, Cohen AD et al. Paraproteinemic neuropathies. Muscle Nerve 2024; 70 (2): 173–179. doi: 10.1002/mus.28164.
48. Min YG, Visentin A, Briani C et al. Neuropathy with anti-myelin-associated glycoprotein antibodies: update on diagnosis, pathophysiology and management. J Neurol Neurosurg Psychiatry 2025; 96 (4): 340–349. doi: 10.1136/jnnp-2024-334678.
49. Klein CJ, Triplett JD, Murray DL et al. Optimizing anti-myelin-associated glycoprotein and IgM-gammopathy testing for neuropathy treatment evaluation. Neurology 2024; 103 (11): e210000. doi: 10.1212/WNL.0000000000210000.
50. Perrain V, Molinier-Frenkel V, Dupuis J et al. Prevalence and spectrum of neuropathies in a cohort of 585 patients with immunoglobulin a monoclonal gammopathy. Eur J Neurol 2025; 32 (2): e70087. doi: 10.1111/ene.70087.
51. Visentin A, Pravato S, Castellani F et al. From biology to treatment of monoclonal gammopathies of neurological significance. Cancers (Basel) 2022; 14 (6): 1562. doi: 10.3390/cancers14061562.
52. Briani C, Visentin A, Cerri F et a. From pathogenesis to personalized treatments of neuropathies in hematological malignancies. J Peripher Nerv Syst 2020; 25 (3): 212–221. doi: 10.1111/jns.12405.
53. Ripa M, Schipa C, Aceto P et al. Exploring the ocular involvement in multiple myeloma: a comprehensive review of 70-year clinical studies. Int Ophthalmol 2025; 45 (1): 89. doi: 10.1007/s10792-025-03467-9.
54. Al Hariri M, Munder M, Lisch W et al. Prevalence of corneal findings and their interrelation with hematological findings in monoclonal gammopathy. PLoS One 2022; 17 (10): e0276048. doi: 10.1371/journal.pone.0276048.
55. Nouira C, Ghazal W, Panthier C et al. Monoclonal gammopathy presenting with paraproteinemic keratopathy documented with anterior segment OCT: a case report. BMC Ophthalmol 2025; 25 (1): 356. doi: 10.1186/s12886-025-04161-1.
56. Garderet L, Al Hariri M, Wasielica-Poslednik J et al. Monoclonal gammopathy of ocular significance (MGOS) – a short survey of corneal manifestations and treatment outcomes. Leuk Lymphoma 2022; 63 (4): 984–990. doi: 10.1080/10428194.2021.2008385.
57. Kormányos K, Kovács K, Németh O et al. Ocular signs and ocular comorbidities in monoclonal gammopathy: analysis of 80 subjects. J Ophthalmol 2021; 2021 : 9982875. doi: 10.1155/2021/9982875.
58. Singh RB, Singhal S, Sinha S et al. Ocular complications of plasma cell dyscrasias. Eur J Ophthalmol 2023; 33 (5): 1786–1800. doi: 10.1177/11206721231155974.
59. Lindemann C, Enders P, Brinkkoetter PT et al. Crystalline deposits in the cornea and various areas of the kidney as symptoms of an underlying monoclonal gammopathy: a case report. BMC Nephrol 2021; 22 (1): 117. doi: 10.1186/s12882-021-02309-x.
60. Karakus S, Gottsch JD, Caturegli P et al. Monoclonal gammopathy of „ocular“ significance. Am J Ophthalmol Case Rep 2019; 15 : 100471. doi: 10.1016/j.ajoc.2019.100471.
61. Skalicka P, Dudakova L, Palos M et al. Paraproteinemic keratopathy associated withmonoclonal gammopathy of undetermined significance (MGUS): clinical findings in twelve patiens including recurrence after keratoplasty. Acta Ophthalmol 2019; 97 (7): e987–e992. doi: 10.1111/aos.14123.
62. Del-Pozo-Lérida S, Llopart AS, Widmer-Pintos J et al. Bilateral corneal copper deposition in monoclonal gammopathy of undetermined significance: diagnostic insights and treatment with descemet membrane endothelial keratoplasty and descemet stripping only. Cornea 2025; 44 (9): 1192–1196. doi: 10.1097/ICO.0000000000003880.
63. Thomson AC, Raviskanthan S, Mortensen PW et al. Paraneoplastic autoimmune retinopathy associated with non-IgM lymphoplasmacytic lymphoma. J Neuroophthalmol 2023; 43 (4): e184–e187. doi: 10.1097/WNO.0000000000001450.
64. Bergman Z, Mohammed T, Schocket L et al. Autoimmune retinopathy in a patient with smoldering multiple myeloma: a case report. Doc Ophthalmol 2024; 148 (3): 167–171. doi: 10.1007/s10633-024-09965-y.
65. Clarkson B, Thompson D, Horwith M et al. Cyclical edema and shock due to increased capillary permeability. Am J Med 1960; 29 : 193–216. doi: 10.1016/0002-9343 (60) 90018-8.
66. Ounci-Essad, Bouchlarhem A, Lamzouri O et al. Consider systemic capillary leak syndrome in monoclonal gammopathy with shock. Ann Med Surg (Lond) 2021; 72 : 103013. doi: 10.1016/j.amsu.2021.103013.
67. Doubek M, Brychtové Y, Tomíška M et al. Idiopathic systemic capillary leak syndrome misdiagnosed and treated as polycythemia vera. Acta Haematol 2005; 113 (2): 150–151. doi: 10.1159/000083455.
68. Pecker MS, Hammudi M, Melchio R et al. Management of acute episodes of Clarkson disease (monoclonal gammopathy-associated systemic capillary leak syndrome) with intravenous immunoglobulins. Ann Intern Med Clin Cases 2022; 1 (6). doi: 10.7326/aimcc.2022.0496.
69. Moyon Q, Pineton de Chambrun M, Gousseff M et al. Intravenous immunoglobulins tapering and withdrawal in systemic capillary leak syndrome (Clarkson disease). J Allergy Clin Immunol Pract 2022; 10 (11): 2889–2895. doi: 10.1016/j.jaip.2022.07.006.
70. Pineton de Chambrun M, Gousseff M, Mauhin W et al. Intravenous immunoglobulins improve survival in monoclonal gammopathy-associated systemic capillary-leak syndrome. Am J Med 2017; 130 (10): 1219.e19–1219.e27. doi: 10.1016/j.amjmed.2017.05.023.
71. Hermida G, Alvarez-Nuño R, San Miguel-Izquierdo J et al. Long term remission of capillary leak syndrome associated with monoclonal gammopathy with progression to multiple myeloma after autologous stem cell transplantation: a case report and review of the literature. Oncol Ther 2024; 12 (1): 183–188. doi: 10.1007/s40487-024-00263-w.
72. Bu Q, Zhou H, Gao W et al. Systemic capillary leak syndrome associated with smouldering multiple myeloma treated by bortezomib plus dexamethasone: a case report. Br J Haematol 2025. doi: 10.1111/bjh.20193.
73. Pinto AR, Carolino F. Acute abdominal pain as the initial presentation of an acquired C1 inhibitor deficiency. GE Port J Gastroenterol 2023; 31 (4): 273–277. doi: 10.1159/000533179.
74. Šantavý O, Žák J. Angioedém na podkladě deficitu C1 inhibitoru. Vnitr Lek 2025; 71 (1): 47–49.
75. Sobotková M. Současná doporučení v léčbě hereditárního angioedému. [online]. Dostupné z: https: //farmakoterapeutickarevue.cz/cs/soucasna-doporuceni-v-lecbe-hereditarniho-angioedemu.
76. Sobotková M, Segethová J. Získaný angioedém s deficitem C1 inhibitoru u pacientky s B-lymfomem nízké malignity a efekt léčby základního onemocnění na projevy angioedému. Trans Hematol Dnes 2017; 23 (3): 145–150.
77. Sobotkova M, Zachova R, Hakl R et al. Acquired angioedema with C1 inhibitor deficiency: occurrence, clinical features, and management: a Nationwide retrospective study in the Czech Republic patients. Int Arch Allergy Immunol 2021; 182 (7): 642–649. doi: 10.1159/000512933.
78. Sobotková M, Zachová R, Hakl R et al. Získaný angioedém s deficitem C1 inhibitoru – výsledky retrospektivní studie z České republiky. 2020 [online]. Dostupné z: https: //uia.fnplzen.cz/sites//users/uia2/Ziskany%20angioedem%20s%20deficitem%20C1%20inhibitoru-vysledky%20retrospektivni%20studie%20z%20%C4% 8CR.pdf.
79. Lahuna C, Defendi F, Bouillet L et al Angioedema due to acquired C1-inhibitor deficiency associated with monoclonal gammopathies of undetermined significance characteristics of a French national cohort. J Allergy Clin Immunol Pract 2024; 12 (12): 3283–3291. doi: 10.1016/j.jaip.2024.09.016.
80. Stammler R, Defendi F, Aubineau M et al. Angioedema due to acquired C1-inhibitor deficiency without hematological condition: a multicenter French cohort study of 34 patients. J Allergy Clin Immunol Pract 2025; 13 (3): 542–550.e2. doi: 10.1016/j.jaip.2024.12.027.
81. Petersen RS, Fijen LM, Franssen LE et al. Daratumumab-based treatment of monoclonal gammopathy-associated angioedema due to acquired C1-inhibitor deficiency. J Allergy Clin Immunol Glob 2024; 3 (4): 100322. doi: 10.1016/j.jacig.2024.100322.
82. Kalmi G, Nguyen Y, Amarger S et al. Efficacy and safety of rituximab-based treatments in angioedema with acquired C1-inhibitor deficiency. J Allergy Clin Immunol Pract 2024; 12 (1): 212–222. doi: 10.1016/j.jaip.2023.10.017.
83. Dispenzieri A. Monoclonal gammopathies of clinical significance. Hematology Am Soc Hematol Educ Program 2020; 2020 (1): 380–388. doi: 10.1182/hematology.2020000122.
84. Kušnierová P. Laboratorní diagnostika monoklonálních gamapatií. Ostravská univerzita 2022.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
